Dan Trang
Stonegate Securities
Recent Quotes
"RVX is set to begin its BETonMACE trial in fall 2015."
—
Dan Trang, Stonegate Capital Partners
(8/17/15)
more >
"RVX is uniquely positioned to leverage its novel RVX-208 in cardiovascular disease."
—
Dan Trang, Stonegate Capital Partners
(4/1/15)
more >
"The successful completion of the Phase 3 study is expected to enhance the value of CVM's business."
—
Dan Trang, Stonegate Capital Partners
(2/11/15)
more >
"CYTX continues its growth story."
—
Dan Trang, Stonegate Securities
(3/18/14)
more >
"We initiate coverage of FDNH and believe the future is bright for the company."
—
Dan Trang, Stonegate Securities
(2/12/14)
more >
"Walgreens' procurement of OCLS' Puracyn products is positive."
—
Dan Trang, Stonegate Securities
(11/25/13)
more >
